Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
Abstract Inhaled treprostinil was approved recently for interstitial lung disease‐pulmonary hypertension; however, efficacy in “real‐world” populations is not known. We designed a protocol and report our experience evaluating 10 patients referred for therapy. Misdiagnosis at presentation was common;...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-07-01
|
| Series: | Pulmonary Circulation |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/pul2.12126 |
| _version_ | 1817967920254287872 |
|---|---|
| author | Shelsey W. Johnson Lauren Finlay Stephen C. Mathai Ronald H. Goldstein Bradley A. Maron |
| author_facet | Shelsey W. Johnson Lauren Finlay Stephen C. Mathai Ronald H. Goldstein Bradley A. Maron |
| author_sort | Shelsey W. Johnson |
| collection | DOAJ |
| description | Abstract Inhaled treprostinil was approved recently for interstitial lung disease‐pulmonary hypertension; however, efficacy in “real‐world” populations is not known. We designed a protocol and report our experience evaluating 10 patients referred for therapy. Misdiagnosis at presentation was common; ultimately, three patients (30%) were prescribed drug. This protocol offers an opportunity to standardize longitudinal assessment of inhaled treprostinil in clinical practice. |
| first_indexed | 2024-04-13T07:06:31Z |
| format | Article |
| id | doaj.art-5707562ec5764b82986cb9cdf09a7e95 |
| institution | Directory Open Access Journal |
| issn | 2045-8940 |
| language | English |
| last_indexed | 2024-04-13T07:06:31Z |
| publishDate | 2022-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Circulation |
| spelling | doaj.art-5707562ec5764b82986cb9cdf09a7e952022-12-22T02:56:58ZengWileyPulmonary Circulation2045-89402022-07-01123n/an/a10.1002/pul2.12126Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribingShelsey W. Johnson0Lauren Finlay1Stephen C. Mathai2Ronald H. Goldstein3Bradley A. Maron4Department of Pulmonary, Allergy, Sleep, and Critical Care Medicine, VA Boston Healthcare System Boston Massachusetts USADepartment of Pharmacy VA Boston Healthcare System Boston Massachusetts USADepartment of Pulmonary and Critical Care Medicine Johns Hopkins University, and Johns Hopkins School of Medicine Baltimore Maryland USADepartment of Pulmonary, Allergy, Sleep, and Critical Care Medicine, VA Boston Healthcare System Boston Massachusetts USADepartment of Pulmonary, Allergy, Sleep, and Critical Care Medicine, VA Boston Healthcare System Boston Massachusetts USAAbstract Inhaled treprostinil was approved recently for interstitial lung disease‐pulmonary hypertension; however, efficacy in “real‐world” populations is not known. We designed a protocol and report our experience evaluating 10 patients referred for therapy. Misdiagnosis at presentation was common; ultimately, three patients (30%) were prescribed drug. This protocol offers an opportunity to standardize longitudinal assessment of inhaled treprostinil in clinical practice.https://doi.org/10.1002/pul2.12126Group 3 pulmonary hypertensioninhaled treprostinilinterstitial lung diseasepulmonary hypertension |
| spellingShingle | Shelsey W. Johnson Lauren Finlay Stephen C. Mathai Ronald H. Goldstein Bradley A. Maron Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing Pulmonary Circulation Group 3 pulmonary hypertension inhaled treprostinil interstitial lung disease pulmonary hypertension |
| title | Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing |
| title_full | Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing |
| title_fullStr | Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing |
| title_full_unstemmed | Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing |
| title_short | Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing |
| title_sort | real world use of inhaled treprostinil for lung disease pulmonary hypertension a protocol for patient evaluation and prescribing |
| topic | Group 3 pulmonary hypertension inhaled treprostinil interstitial lung disease pulmonary hypertension |
| url | https://doi.org/10.1002/pul2.12126 |
| work_keys_str_mv | AT shelseywjohnson realworlduseofinhaledtreprostinilforlungdiseasepulmonaryhypertensionaprotocolforpatientevaluationandprescribing AT laurenfinlay realworlduseofinhaledtreprostinilforlungdiseasepulmonaryhypertensionaprotocolforpatientevaluationandprescribing AT stephencmathai realworlduseofinhaledtreprostinilforlungdiseasepulmonaryhypertensionaprotocolforpatientevaluationandprescribing AT ronaldhgoldstein realworlduseofinhaledtreprostinilforlungdiseasepulmonaryhypertensionaprotocolforpatientevaluationandprescribing AT bradleyamaron realworlduseofinhaledtreprostinilforlungdiseasepulmonaryhypertensionaprotocolforpatientevaluationandprescribing |